Log in

LON:SLNSilence Therapeutics Share Price, Forecast & News

GBX 437
-21.00 (-4.59 %)
(As of 06/5/2020 06:24 AM ET)
Today's Range
Now: GBX 437
50-Day Range
MA: GBX 424.76
52-Week Range
Now: GBX 437
Volume10,583 shs
Average Volume13,380 shs
Market Capitalization£361.82 million
P/E RatioN/A
Dividend YieldN/A
Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Read More
Silence Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual Sales£244,000.00
Cash FlowGBX 41.29 per share
Book ValueGBX 26.70 per share



Market Cap£361.82 million
Next Earnings DateN/A
OptionableNot Optionable

Receive SLN News and Ratings via Email

Sign-up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.

Silence Therapeutics (LON:SLN) Frequently Asked Questions

How has Silence Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Silence Therapeutics' stock was trading at GBX 470 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SLN shares have decreased by 7.0% and is now trading at GBX 437. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Silence Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Silence Therapeutics.

How were Silence Therapeutics' earnings last quarter?

Silence Therapeutics plc (LON:SLN) posted its earnings results on Tuesday, September, 11th. The company reported ($12.40) earnings per share (EPS) for the quarter. View Silence Therapeutics' earnings history.

What price target have analysts set for SLN?

1 equities research analysts have issued 12-month price objectives for Silence Therapeutics' stock. Their forecasts range from GBX 605 to GBX 605. On average, they anticipate Silence Therapeutics' stock price to reach GBX 605 in the next twelve months. This suggests a possible upside of 38.4% from the stock's current price. View analysts' price targets for Silence Therapeutics.

Has Silence Therapeutics been receiving favorable news coverage?

Media stories about SLN stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Silence Therapeutics earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future. View the latest news aboutSilence Therapeutics.

Who are some of Silence Therapeutics' key competitors?

What other stocks do shareholders of Silence Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Silence Therapeutics investors own include Arch Therapeutics (ARTH), QuickLogic (QUIK), Asiamet Resources (ARS), ArcBest (ARCB), American Renal Associates (ARA), Apergy (APY), ANCHIANO THERAP/S (ANCN), Aileron Therapeutics (ALRN), Alkermes (ALKS) and Alfa Financial Software (ALFA).

Who are Silence Therapeutics' key executives?

Silence Therapeutics' management team includes the following people:
  • Dr. David Horn Solomon, CEO & Director (Age 59)
  • Dr. Rob Quinn, Chief Financial Officer
  • Dr. Mark Cameron, Head of Chemistry
  • Mr. Richard Jenkins, Head of Clinical Devel.

What is Silence Therapeutics' stock symbol?

Silence Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SLN."

How do I buy shares of Silence Therapeutics?

Shares of SLN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Silence Therapeutics' stock price today?

One share of SLN stock can currently be purchased for approximately GBX 437.

How big of a company is Silence Therapeutics?

Silence Therapeutics has a market capitalization of £361.82 million and generates £244,000.00 in revenue each year.

What is Silence Therapeutics' official website?

The official website for Silence Therapeutics is www.silence-therapeutics.com.

How can I contact Silence Therapeutics?

Silence Therapeutics' mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The company can be reached via phone at +44-20-34576900.

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.